Find clinical trials for Melanoma in Warszawa, Mazowieckie
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Melanoma trials near Warszawa, Mazowieckie, POL:
therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...
Phase 2, Phase 3
Warsaw, Poland and 70 other locations
binimetinib, and pembrolizumab) given together for the treatment of melanoma that:is advanced or metastatic (spread to other parts of the bo...
Phase 3
Warszawa, Poland and 227 other locations
the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...
Phase 3
Warszawa, Poland and 154 other locations
medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...
Phase 2
Warszawa, Poland and 62 other locations
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investiga...
Phase 2
Warsaw, Poland and 55 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Warszawa, Poland and 63 other locations
antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotini...
Phase 2, Phase 3
Warsaw, Poland and 62 other locations
with previously untreated unresectable or metastatic (advanced) melanoma.Patients will be stratified on the basis of the following factors; ...
Phase 3
Warsaw, Masovian, Poland and 111 other locations
patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...
Phase 2
Warsaw, Poland and 52 other locations
(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...
Phase 3
Warszawa, Poland and 178 other locations
Clinical trials
Research sites
Resources
Legal